Aktis Oncology (AKTS) Projected to Post Earnings on Thursday

Aktis Oncology (NASDAQ:AKTS) is anticipated to post its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($0.47) per share and revenue of $4.02 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. On average, analysts expect Aktis Oncology to post ($1.84) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.

Aktis Oncology Price Performance

Shares of NASDAQ AKTS opened at $15.20 on Thursday. The company’s fifty day moving average is $19.93 and its 200-day moving average is $20.94. Aktis Oncology has a twelve month low of $13.96 and a twelve month high of $34.19.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AKTS. JPMorgan Chase & Co. raised their price objective on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Oppenheimer started coverage on Aktis Oncology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 target price for the company. BMO Capital Markets started coverage on Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price for the company. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $35.62.

About Aktis Oncology

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is directed primarily toward therapies for solid tumors, an area where it seeks to improve the ability of the immune system to recognize and eliminate cancer cells.

Aktis Oncology is developing a pipeline of targeted oncology candidates based on proprietary immune-cell engagement technologies. These therapies are intended to direct immune cells toward tumor-associated targets and potentially address cancers that are difficult to treat with existing immunotherapies.

The company’s programs remain in development, and publicly available information about its commercial products, geographic operations, and leadership is limited.